Loading
Liver Disease Diagnosis and Treatment / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
BMC Endocrine Disorders · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This cross-sectional study of 570 older men found that novel lipid and adiposity indices (particularly LAP and VAI) distinguished metabolic phenotypes within obesity categories, while visceral fat thickness and liver stiffness correlated with obesity phenotype. The findings are based on surrogate imaging and biochemical measures without clinical hard endpoints and are restricted to an exclusively male, older population.
Cross-sectional cohort study. Men aged 50–80 years from North Iran enrolled in the PolyIran-Liver cohort (nested within Golestan Cohort Study); stratified by BMI and metabolic syndrome status.. n = 570. North Iran (Golestan region).
VFT, LS, and BAI showed significant differences between obesity groups with similar metabolic conditions TyG-index and VAI showed significant differences between metabolically healthy and unhealthy groups within the same obesity categories LAP was significantly different between obesity groups with similar metabolic conditions and metabolic groups with similar obesity status
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
LAP and VAI may offer practical, low-cost tools for metabolic risk stratification in older men; however, the lack of clinical endpoints and restriction to a male, older population limit immediate clinical application and warrant prospective validation in diverse populations.
Cross-sectional study in a single-sex, geographically limited cohort using surrogate measures (visceral fat, liver stiffness, lipid indices) without hard clinical outcomes; findings are descriptive and hypothesis-generating rather than definitive.
As stated by the source record.
Quoted from the source exactly as published.
LAP and VAI may offer practical, low-cost tools for metabolic risk stratification in older men; however, the lack of clinical endpoints and restriction to a male, older population limit immediate clinical application and warrant prospective validation in diverse populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity is a global, multifactorial, chronic disease associated with an increased risk of various health problems, including cardiometabolic diseases. While body mass index (BMI) is widely used as an indicator of obesity, its limitations in distinguishing between fat mass and free-fat mass have led to the exploration of alternative obesity indices like visceral adiposity index (VAI), body adiposity index (BAI), Triglyceride-glucose Index (TYG-index), and lipid accumulation product (LAP). Herein, we investigate the levels of these novel indices, visceral fat thickness (VFT), liver stiffness (LS), and carotid intima-media thickness (CIMT) in obesity phenotypes. This study utilized part of the pre-intervention (baseline) data from the PolyIran-Liver cohort (ClinicalTrials.gov ID: NCT01245608; registration date: 2010-11-19), nested within the Golestan Cohort Study in North Iran. This cross-sectional study included men aged 50–80 years ( n = 570). By combining BMI and metabolic syndrome, we defined six groups: metabolically healthy obese (MHO), metabolically unhealthy obese (MUO), metabolically healthy overweight (MHOW), metabolically unhealthy overweight (MUOW), metabolically healthy normal-weight (MHNW), and metabolically unhealthy normal-weight (MUNW). VFT and LS were measured by ultrasonography, and novel indices (VAI, LAP, BAI, Tyg-index) were calculated. We found no significant difference in CIMT levels between different phenotypes. VFT, LS, and BAI showed significant differences between obesity groups with similar metabolic conditions. TyG-index and VAI showed significant differences between metabolically healthy and unhealthy groups within the same obesity categories. LAP was significantly different between obesity groups with similar metabolic conditions and metabolic groups with similar obesity status. The odds ratio for elevated LS was significant for MUO, MUOW, and MHO compared to the healthy phenotype. LAP odds ratio was significantly elevated in all groups compared to the healthy population. Multiple linear regression analysis for VFT, LS, and CIMT further confirmed our findings. VFT, LS, and BAI distinguished obesity phenotypes, while TyG-index and VAI differentiated metabolic groups with similar obesity levels, and LAP showed differentiation across both categories. Accordingly, LAP and VAI can be considered as practical and low-cost indices that may help with metabolic risk stratification. No significant differences in CIMT were observed across obesity phenotypes in our cohort. These findings should be interpreted within the context of an exclusively male, older population and should not be directly generalized to women or younger individuals.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.